Licensing and co-development agreement with Xbiome

In January 2022, Aurealis Therapeutics signed an exclusive license and collaboration agreement with Xbiome for the clinical development and commercialization of the therapy AUP-16 for Diabetic Foot Ulcers, other chronic wounds and inflammatory diseases in Greater China. 

Xbiome acquired exclusive development and commercial rights for all human use to Aurealis Therapeutics AUP-16 in Mainland China, Hong Kong, Macao and Taiwan. Xbiome is responsible for all clinical and other development, regulatory submissions, and commercialization of the licensed products in the licensed territory. Aurealis Therapeutics retains full rights to AUP-16 outside for the specified territory and will continue to lead the global development of the drug candidate.

Aurealis Therapeutics received an upfront payment, will receive development milestone payments and is eligible to receive commercial milestone payments and royalties on product sales. All together this could amount to 139 million USD plus single to double digit digit ascending royalties on product sales.

Xbiome is an industry-leading

clinical stage AI-based microbiome drug development company headquartered in China. The company is dedicated to tackling unmet medical needs through various modalities of microbiome therapeutics. In June 2021, Xbiome obtained IND approval in USA for its lead program XBI-302, an orally administered FMT therapy for graft-versus-host disease (GvHD).



Aurealis Therapeutics offers breakthrough solutions for massive unmet needs and major pharmaceutical markets. We are eager to meet strategic partners and investors to ensure these breakthroughs are made available to all the patients who need them. 


Continous, on-site action

Low Cost

Low manufacturing cost


Local administration


Logistically stable
No special handling required

Chronic wounds, such as Diabetic Foot Ulcers, venous leg ulcers, and pressure ulcers, contribute major costs to healthcare systems and societies. Just in the USA, 8.2 million patients are impacted annually by non-healing wounds and related complications. The global market for chronic wound care is estimated at 10 billion USD, with a 5% annual growth rate, revealing a need for better treatment options than the ones currently available. The market is dominated by basic wound care products, advanced dressings, cellular and tissue-based products, and medical devices. No approved drugs are marketed in USA and Europe, posing an untapped market for the first movers. The outcome of the AUP-16 Phase 1 study in Diabetic Foot Ulcers makes us confident that we can change the treatment paradigm of chronic wounds.

Oncology dominates the pharmaceutical market (>160 billion USD in sales in 2021); still deadly cancers represent a massive unmet medical need. For example, according to WHO, every year 313 959 women are diagnosed and 207 252 of them die due to Ovarian Cancer.  AUP-55 pre-clinical data in advanced Ovarian Cancer and Peritoneal Carcinomatosis demonstrates the flexibility and ubiquity of Aurealis Therapeutics cell and gene therapy platform in oncology.

Aurealis Therapeutics is an innovative cell and gene therapy platform company offering world-first 4-in-1 therapies with superior efficacy to these unmet medical indications and market. Our disruptive  technology platform clearly differentiates from other therapeutic options:

  • Enables 4-in-1 targeting
  • Non-pathogenic
  • Controllable when administered
  • Cost of goods and manufacturing scalability
  • Easy to use

Aurealis Therapeutics cell and gene therapy platform is a game-changer for chronic wounds and deadly cancers; this therapy platform solves the problems of efficacy, safety, scale-up, cost, and delivery of the therapeutic agents.